ANDA 211012, held by Ajanta Pharma Ltd. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 211012 (Doxycycline Hyclate), held by Ajanta Pharma Ltd, was first approved by FDA on Sep 24, 2018, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate, USP and other antibacterial drugs, doxycycline hyclate capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2018 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 50MG BASE · capsule;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 100MG BASE · capsule;oral | Doxycycline Hyclate | Discontinued |
| Jul 31, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 31, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 31, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 5, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 24, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters